The Effects of Pancreastatin on Insulin Resistance and fetal birth weight in patients with Gestational Diabetes
Project no. 23790 · Status: Kapanmış · 2022
Summary
<p>Gestational Diabetes is one of the most common medical complications of pregnancy.</p><p> Pregnancy is primarily accompanied by an insulin resistance mediated by placental secretion of diabetogenic hormones including growth hormone (GH), corticotrophin-releasing hormone (CRH) , human corionic somatomammotrophin (hCS or human placental lactogen -hPL) , prolactin and progesterone. Pancreastatin is a regulatory peptide derived from the intracellular and/or extracellular processing of chromogranin A, a soluble acidic protein stored in the secretory granules of the neuroendocrine system. Several reports have indicated the role of pancreastatin in modulation of energy metabolism and counteracting the effects of insulin.</p><p>Increased plasma pancreastatin levels were reported in gestational diabetic patients. This counter-regulatory hormone may play a role in the insulin resistance in the pathogenesis of gestational diabetes.</p><p>In the present study by comparing plasma pancreastatin levels of gestational diabetic pregnancies with normal glucose tolerant pregnancies we aimed to contribute to scientific literature which we considered scant in this regard.</p><p>70 gestational diabetic and 70 normal OGTT pregnancies at 24th-28th weeks,undergoing screening by a 75 gr OGTT will be recruited. Anthropometric measurements, medical history will be recorded, blood will be drawn for pancreastatin and medical record will be reviewed for birth weight. Patient recruitment will be completed at 9 months. Then biochemical study for pancreastatin and article writing process will ensue. Total of 12 months duration is estimated.</p><p><br></p><p> </p><p> </p>